{"classes":[{"categories":[{"measurements":[{"groupId":"OG001","spread":"1.6","value":"4.6"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"10"}],"units":"Participants"}],"description":"Median time to local failure based on regional or distant metastatic disease","dispersionType":"Standard Deviation","groups":[{"description":"Radiation: CyberKnife Stereotactic Radiosurgery boost (2 fractionated doses) beginning 4-8 weeks after completion of standard therapy.\n\nstereotactic radiosurgery: Given in 2 fractionated doses or 5 fractionated doses","id":"OG000","title":"Group 1 (CK SRS Boost Therapy)"},{"description":"Radiation : CyberKnife® stereotactic radiosurgery salvage therapy (5 fractions) 3 times weekly.\n\nstereotactic radiosurgery: Given in 2 fractionated doses or 5 fractionated doses","id":"OG001","title":"Group 2 (CK SRS Salvage Therapy)"}],"paramType":"MEDIAN","populationDescription":"Boost subjects were not evaluable.","reportingStatus":"POSTED","timeFrame":"1 year","title":"Duration of Local Control","type":"PRIMARY","unitOfMeasure":"number of months to local failure"}